ATE283047T1 - Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose - Google Patents
Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple skleroseInfo
- Publication number
- ATE283047T1 ATE283047T1 AT98936715T AT98936715T ATE283047T1 AT E283047 T1 ATE283047 T1 AT E283047T1 AT 98936715 T AT98936715 T AT 98936715T AT 98936715 T AT98936715 T AT 98936715T AT E283047 T1 ATE283047 T1 AT E283047T1
- Authority
- AT
- Austria
- Prior art keywords
- ibudilast
- multiple sclerosis
- treatment
- production
- medicinal product
- Prior art date
Links
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 title abstract 3
- 229960002491 ibudilast Drugs 0.000 title abstract 3
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 3
- 229940126601 medicinal product Drugs 0.000 title 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Forklifts And Lifting Vehicles (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP1998/003548 WO2000009127A1 (en) | 1998-08-10 | 1998-08-10 | Remedies for multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE283047T1 true ATE283047T1 (de) | 2004-12-15 |
Family
ID=14208769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98936715T ATE283047T1 (de) | 1998-08-10 | 1998-08-10 | Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6395747B1 (de) |
| EP (1) | EP1106178B1 (de) |
| JP (1) | JP4828003B2 (de) |
| AT (1) | ATE283047T1 (de) |
| AU (1) | AU8562198A (de) |
| CA (1) | CA2339934C (de) |
| DE (1) | DE69827853T2 (de) |
| DK (1) | DK1106178T3 (de) |
| ES (1) | ES2231998T3 (de) |
| PT (1) | PT1106178E (de) |
| WO (1) | WO2000009127A1 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4589122B2 (ja) | 2002-12-03 | 2010-12-01 | 杏林製薬株式会社 | ホスホジエステラーゼ１０ａ阻害剤 |
| BRPI0416812A (pt) * | 2003-11-21 | 2007-03-06 | Combinatorx Inc | métodos e reagentes para o tratamento de desordens inflamatórias |
| US20060093578A1 (en) * | 2004-11-04 | 2006-05-04 | Kyorin Pharmaceutical Co., Ltd. | Method and composition for treating multiple sclerosis |
| AU2005314133B2 (en) * | 2004-12-06 | 2012-03-08 | Medicinova, Inc. | Ibudilast for treating neuropathic pain and associated syndromes |
| KR100780479B1 (ko) | 2006-05-08 | 2007-11-28 | 윈셋파마 주식회사 | 이부딜라스트 함유 경구용 제제 및 이의 제조방법 |
| EP2026804A1 (de) * | 2006-05-31 | 2009-02-25 | Avigen, Inc. | Ibudilast zur hemmung der aktivität des makrophagen-migrationshemmungsfaktors |
| EP2131841B1 (de) * | 2007-01-30 | 2012-08-01 | Avigen, Inc. | Verfahren zur behandlung von akuten schmerzen |
| US20080287402A1 (en) * | 2007-05-03 | 2008-11-20 | Johnson Kirk W | Use of a glial attenuator to prevent amplified pain responses caused by glial priming |
| CA2693697C (en) | 2007-07-11 | 2017-07-25 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| EP3558301A4 (de) | 2016-12-22 | 2020-07-29 | MediciNova, Inc. | Verfahren zur behandlung von glioblastoma multiforme mit ibudilast |
| US20190247369A1 (en) * | 2018-02-12 | 2019-08-15 | Medicinova, Inc. | Methods of suppressing myeloid-derived suppressor cells in patients |
| JP2021512921A (ja) | 2018-02-12 | 2021-05-20 | メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． | 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン |
| US20210145838A1 (en) * | 2018-04-05 | 2021-05-20 | Universiteit Hasselt | Selective pde4d inhibitors against demyelinating diseases |
| CN112770748A (zh) | 2018-10-09 | 2021-05-07 | 美迪诺亚公司 | 异丁司特和干扰素-β的组合及其使用方法 |
| ES2970996T3 (es) | 2018-10-19 | 2024-06-03 | Medicinova Inc | Tratamiento de la lesión macular asociada a la esclerosis múltiple con ibudilast |
| WO2020251748A1 (en) * | 2019-06-11 | 2020-12-17 | Yale University | Novel treatment for wolfram syndrome |
| WO2021061554A1 (en) | 2019-09-23 | 2021-04-01 | Medicinova, Inc. | Ibudilast oral formulations and methods of using same |
| CA3174413A1 (en) | 2020-04-06 | 2021-10-14 | Yuichi Iwaki | Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast |
| CN116887829A (zh) | 2021-01-29 | 2023-10-13 | 美迪诺亚公司 | 治疗化学气体暴露的方法 |
| EP4376838A1 (de) | 2021-07-26 | 2024-06-05 | MediciNova, Inc. | Ibudilast zur prävention von augenkrebsmetastasen |
| CN118139619A (zh) | 2021-09-21 | 2024-06-04 | 美迪诺亚公司 | 异丁司特以联合治疗方式用于治疗胶质母细胞瘤 |
| US12042485B2 (en) | 2021-10-07 | 2024-07-23 | Medicinova, Inc. | Methods of minimizing cancer metastasis |
| US12171752B2 (en) | 2022-02-01 | 2024-12-24 | Medicinova, Inc. | Methods of treating post-COVID condition(s) |
| EP4554558A1 (de) | 2022-07-13 | 2025-05-21 | MediciNova, Inc. | Injizierbare formulierungen von ibudilast |
| WO2026060180A1 (en) | 2024-09-11 | 2026-03-19 | Medicinova, Inc. | Modified release formulations of ibudilast |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672622A (en) * | 1994-04-21 | 1997-09-30 | Berlex Laboratories, Inc. | Treatment of multiple sclerosis |
| CA2197984A1 (en) * | 1994-08-29 | 1996-03-07 | Kazuhisa Takayama | Novel naphthyridine derivatives and pharmaceutical compositions thereof |
-
1998
- 1998-08-10 DK DK98936715T patent/DK1106178T3/da active
- 1998-08-10 CA CA002339934A patent/CA2339934C/en not_active Expired - Lifetime
- 1998-08-10 ES ES98936715T patent/ES2231998T3/es not_active Expired - Lifetime
- 1998-08-10 JP JP53649998A patent/JP4828003B2/ja not_active Expired - Lifetime
- 1998-08-10 US US09/762,616 patent/US6395747B1/en not_active Expired - Lifetime
- 1998-08-10 PT PT98936715T patent/PT1106178E/pt unknown
- 1998-08-10 AT AT98936715T patent/ATE283047T1/de active
- 1998-08-10 AU AU85621/98A patent/AU8562198A/en not_active Abandoned
- 1998-08-10 WO PCT/JP1998/003548 patent/WO2000009127A1/ja not_active Ceased
- 1998-08-10 EP EP98936715A patent/EP1106178B1/de not_active Expired - Lifetime
- 1998-08-10 DE DE69827853T patent/DE69827853T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1106178B1 (de) | 2004-11-24 |
| EP1106178A1 (de) | 2001-06-13 |
| WO2000009127A1 (en) | 2000-02-24 |
| DK1106178T3 (da) | 2005-02-28 |
| PT1106178E (pt) | 2005-02-28 |
| CA2339934A1 (en) | 2000-02-24 |
| ES2231998T3 (es) | 2005-05-16 |
| DE69827853T2 (de) | 2005-12-08 |
| EP1106178A4 (de) | 2001-11-21 |
| JP4828003B2 (ja) | 2011-11-30 |
| AU8562198A (en) | 2000-03-06 |
| US6395747B1 (en) | 2002-05-28 |
| DE69827853D1 (de) | 2004-12-30 |
| CA2339934C (en) | 2008-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE283047T1 (de) | Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose | |
| DE3876877D1 (de) | Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus. | |
| DE69201948D1 (de) | Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b. | |
| ATE73331T1 (de) | Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus. | |
| ATE204178T1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
| NO870241L (no) | Hypoglykemiske tiazolidindioner. | |
| HUP9600448A2 (hu) | Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk | |
| ATE191849T1 (de) | Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst | |
| DE3879873D1 (de) | Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| DE59302501D1 (de) | Substituierte Cyclohexan-Derivate, Verfahren zu ihrer Herstellung und die Anwendung der Verbindungen zur Behandlung von Krankheiten | |
| ATE353645T1 (de) | Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia | |
| DE59508961D1 (de) | Verwendung von weihrauch zur behandlung der alzheimer-krankheit | |
| ATE123944T1 (de) | Verwendung von trifluormethylphenyl- tetrahydropyridinen zur herstellung von arzneimitteln zur behandlung anxio-depressiver erkrankungen. | |
| ATE335487T1 (de) | Verwendung von pyridazino 4,5-(b)ö-indole-1- acetamide derivaten zur herstellung eines arzneimittels zur behandlung von durch periphere benzodiazepinrezeptoren-störungen verursachte krankheiten | |
| ATE79257T1 (de) | Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden. | |
| DE69420776D1 (de) | Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer | |
| ATE85334T1 (de) | Bisphenylalkylpiperazin-derivate, verfahren zur herstellung und arzneimittelzubereitung. | |
| TNSN97143A1 (fr) | Derives de trans-piperazine-1-yl-spiro(cyclohexane-1, 1'- isobenzofuranne), procede pour leur preparation et compositions pharmaceutiques les contenant | |
| KR880009957A (ko) | 알킬-치환된 n-벤조피라닐락탐, 이의 제조방법, 이의 용도 및 이들 화합물을 기본으로 하는 약제학적 제제 | |
| DE60108130D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
| ATE169635T1 (de) | Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen | |
| ATE110568T1 (de) | Pharmazeutisches präparat zur behandlung des katarakts. | |
| DE69619868D1 (de) | Piperazinylalkylthiopyrimidin derivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung | |
| ATE181503T1 (de) | Verwendung von idazoxan und derivaten zur herstellung eines arzneimittels zur behandlung von parkinsonismus und seiner evolution | |
| BR9708922A (pt) | Piridil-e pirimidil-piperazinas no tratamento de doenças causadas por substâncias usadas em excesso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1106178 Country of ref document: EP |